Accès gratuit
Numéro
Med Sci (Paris)
Volume 26, Numéro 12, Décembre 2010
Page(s) 1049 - 1055
Section M/S revues
DOI https://doi.org/10.1051/medsci/201026121049
Publié en ligne 15 décembre 2010
  1. Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocrine Rev 1995 ; 16 : 354-69.
  2. Goffin V, Binard N, Touraine P, et al. Prolactin: the new biology of an old hormone. Annu Rev Physiol 2002 ; 64 : 47-67.
  3. Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000 ; 80 : 1523-31.
  4. Clapp C, Aranda J, Gonzales C, et al. Vasohinhibins: endogenous regulators of angiogenesis and vascular function. Trends Endocrinol Metab 2006 ; 17 : 301-7.
  5. Grattan DR, Kokay IC. Prolactin: a pleiotropic neuroendocrine hormone. J Neuroendocrinol 2008 ; 20 : 752-63.
  6. Cruz-Soto ME, Cosio G, Jeziorski MC, et al. Cathepsin D is the primary protease for the generation of adenohypophyseal vasoinhibins: cleavage occurs within the prolactin secretory granules. Endocrinology 2009 ; 150 : 5446-54.
  7. Ben Jonathan N, Mershom JL, Allen DL, et al. Extrapituitary prolactin: distribution, regulation, functions and clinical aspects. Endocr Rev 1996 ; 17 : 639-69.
  8. Lkhider M, Delpal S, Le Provost F, et al. Rat Prolactin synthesis by lactating mammary epithelial cells. FEBS Lett 1997 ; 401 : 117-22.
  9. Lkhider M, Castino R, Bouguyon E, et al. Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions. J CellSci 2004 ; 117 : 5155-64.
  10. Erdmann S, Recken A, Merkwitz C, et al. The expression of prolactin and its cathepsin D-mediated cleavage in the bovine corpus luteum vary with the estrous cycle. Am J Physiol Endocrinol Metab 2007 ; 293 : E1365-77.
  11. Ben-Jonathan N, Lapensee CR, Lapensee EW. What we can learn from rodents about prolactin in humans? Endocrine Rev 2008 ; 29 : 1-41.
  12. Eyal O, Jomain JB, Kessler C, et al. Autocrine prolactin inhibits human uterine decidualization: a novel role for prolactin. Biol Reprod 2007 ; 76 : 777-83.
  13. Härkönen P. Paracrine prolactin may cause prostatic problems. Endocrinology 2003 ; 144 : 2266-8.
  14. Macotela Y, Aguillar MB, Guzmàn-Morales J, et al. Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. J Cell Sci 2006 ; 119 : 1790-800.
  15. Montgomery DW. Prolactin production by immune cells. Lupus 2001 ; 10 : 665-75.
  16. Selle T, Renger I, Labidi S, et al. Rewiewing peripartum cardiomyopathy: current state of knowledge. Future Cardiol 2009 ; 5 : 175-89.
  17. Wood RL, Zhang J, Huang ZM, et al. Prolactin and prolactin receptors in the lacrimal gland. Exp Eye Res 1999 ; 69 : 213-26.
  18. Rivera JC, Aranda J, Riesgo J, et al. Expression and cellular localisation of prolactin and the prolactin receptor in mammalian retina. Exp Eye Res 2008 ; 86 : 314-21.
  19. Ollivier-Bousquet M. Transferrin and prolactin transcytosis in lactating mammary epithelial cell. J Mammary Gland Biol Neoplasia 1998 ; 3 : 303-13.
  20. Truchet S, Ollivier-Bousquet M. Mammary gland secretion: hormonal coordination of endocytosis and exocytosis. Animal 2009 ; 3 : 1733-42.
  21. D’Angelo G, Struman I, Martial J, et al. Activation of mitogen activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 1995 ; 92 : 6374-78.
  22. D’Angelo G, Martini JF, Liri T, et al. 16K human prolactin inhibits vascular endothelial growth in factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol 1999 ; 13 : 692-704.
  23. Tabruyn SP, Sorlet CM, Rentier-Delrue F, et al. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-κB. Mol Endocrinology 2003 ; 17 : 1815-23.
  24. Garcia C, Aranda J, Arnold E, et al. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J Clin Invest 2008 ; 1 18 : 2291-300.
  25. Gonzales C, Corbacho AM, Eiserich JP, et al. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 2004 ; 145 : 5714-22.
  26. Lee SH, Kunz J, Lin SH, et al. 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Res 2007 ; 67 : 11045-53.
  27. Wang Y, Chiu CT, Nakamura T, et al. Elevated prolactin redirects secretory vesicle traffic in rabbit lacrimal acinar cells. Am J Physiol Endocrinol Metab 2007 ; 292 : E1122-34.
  28. Ge G, Fernàndez CA, Moses M, et al. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proc Natl Acad Sci USA 2007 ; 104 : 10010-5.
  29. Piwnica D, Touraine P, Struman I, et al. Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. Mol Endocrinol 2004 ; 18 : 2522-42.
  30. Piwnica D, Fernandez I, Binart N, et al. A new mechanism for prolactin processing into 16K PRL by secreted cathepsin D. Mol Endocrinol 2006 ; 20 : 3263-78.
  31. Castino R, Delpal S, Bouguyon E, et al. Prolactin promotes the secretion of active cathepsin D at the basal side of rat mammary acini. Endocrinology 2008 ; 149 : 4095-105.
  32. Liaudet-Coopman E, Beaujoin M, Derocq D, et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 2006 ; 18 : 167-79.
  33. Swaminathan G, Varghese B, Fuchs SY. Regulation of prolactin receptor levels and activity in breast cancer. J Mammary Gland Biol Neoplasia 2008 ; 13 : 81-91.
  34. Dagvadori Y, Collins S, Jomain JB, et al. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology 2007 ; 148 : 3089-101.
  35. Kim J, Luo W, Chen DT, et al. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 2003 ; 63 : 386-93.
  36. Struman I, Bentzien F, Lee H, et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis; an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA 1999 ; 96 : 1246-51.
  37. Clapp C, Thebault S, Arnold E, et al. Vasoinhibins: novel inhibitors of ocular angiogenesis. Am J Physiol Endocrinol Metab 2008 ; 295 : E772-8.
  38. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007 ; 128 : 589-600.
  39. Triebel J, Huefner M, Ramadori G. Investigation of prolactin-related vasoinhibin in sera from patients with diabetic retinopathy. Eur J Endocrinol 2009 ; 161 : 345-53.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.